Literature DB >> 10432475

Modulation of dialysate levels of dopamine, noradrenaline, and serotonin (5-HT) in the frontal cortex of freely-moving rats by (-)-pindolol alone and in association with 5-HT reuptake inhibitors: comparative roles of beta-adrenergic, 5-HT1A, and 5-HT1B receptors.

A Gobert1, M J Millan.   

Abstract

(-)-Pindolol, which possesses significant affinity for 5-HT1A, 5-HT1B, and beta 1/2-adrenergic receptors (AR)s, dose-dependently increased extracellular levels of dopamine (DA) and noradrenaline (NAD) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats. In distinction, the preferential beta 1-AR antagonist, betaxolol, and the preferential beta 2-AR antagonist, ICI118,551, did not increase basal levels of DA, NAD, or 5-HT. Further, they both dose-dependently and markedly blunted the influence of (-)-pindolol upon DA and NAD levels. The selective 5-HT1A receptor antagonist, WAY100,635, slightly attenuated the (-)-pindolol-induced increase in DA and NAD levels, while the selective 5-HT1B antagonist, SB224,289, was ineffective. These data suggest that (-)-pindolol facilitates frontocortical dopaminergic (and adrenergic) transmission primarily by activation of beta 1/2-ARs and, to a lesser degree, by stimulation of 5-HT1A receptors, whereas 5-HT1B receptors are not involved. (-)-Pindolol potentiated the increase in FCX levels of 5-HT elicited by the 5-HT reuptake inhibitors, fluoxetine and duloxetine, and also enhanced their ability to elevate FCX levels of DA--though not of NAD. In contrast to (-)-pindolol, betaxolol and ICI118,551 did not affect the actions of fluoxetine, whereas both WAY100,635 and SB224,289 potentiated the increase in levels of 5-HT--but not DA or NAD levels--elicited by fluoxetine. In conclusion, (-)-pindolol modulates, both alone and together with 5-HT reuptake inhibitors, dopaminergic, adrenergic, and serotonergic transmission in the FCX via a complex pattern of actions at beta 1/2-ARs, 5-HT1A, and 5-HT1B receptors. These findings have important implications for clinical studies of the influence of (-)-pindolol upon the actions of antidepressant agents.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10432475     DOI: 10.1016/S0893-133X(99)00035-4

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  15 in total

1.  Antagonism of the antidepressant-like effects of clenbuterol by central administration of beta-adrenergic antagonists in rats.

Authors:  Han-Ting Zhang; Ying Huang; James M O'Donnell
Journal:  Psychopharmacology (Berl)       Date:  2003-07-25       Impact factor: 4.530

2.  The alpha2 adrenergic receptor antagonist idazoxan, but not the serotonin-2A receptor antagonist M100907, partially attenuated reward deficits associated with nicotine, but not amphetamine, withdrawal in rats.

Authors:  Svetlana Semenova; Athina Markou
Journal:  Eur Neuropsychopharmacol       Date:  2010-06-03       Impact factor: 4.600

3.  Potentiation of the antinociceptive effect of clomipramine by a 5-ht(1A) antagonist in neuropathic pain in rats.

Authors:  D Ardid; A Alloui; G Brousse; D Jourdan; P Picard; C Dubray; A Eschalier
Journal:  Br J Pharmacol       Date:  2001-03       Impact factor: 8.739

4.  Monitoring extracellular dopamine in the rat nucleus accumbens shell and core during acquisition and maintenance of intravenous WIN 55,212-2 self-administration.

Authors:  Daniele Lecca; Fabio Cacciapaglia; Valentina Valentini; Gaetano Di Chiara
Journal:  Psychopharmacology (Berl)       Date:  2006-07-19       Impact factor: 4.530

Review 5.  Adjunctive 5-Hydroxytryptophan Slow-Release for Treatment-Resistant Depression: Clinical and Preclinical Rationale.

Authors:  Jacob P R Jacobsen; Andrew D Krystal; K Ranga R Krishnan; Marc G Caron
Journal:  Trends Pharmacol Sci       Date:  2016-09-28       Impact factor: 14.819

6.  Differential impact of pavlovian drug conditioned stimuli on in vivo dopamine transmission in the rat accumbens shell and core and in the prefrontal cortex.

Authors:  Valentina Bassareo; Maria Antonietta De Luca; Gaetano Di Chiara
Journal:  Psychopharmacology (Berl)       Date:  2006-10-28       Impact factor: 4.530

7.  A new strategy for antidepressant prescription.

Authors:  Francis Lavergne; Thérèse M Jay
Journal:  Front Neurosci       Date:  2010-11-19       Impact factor: 4.677

8.  Knockout of the norepinephrine transporter and pharmacologically diverse antidepressants prevent behavioral and brain neurotrophin alterations in two chronic stress models of depression.

Authors:  Britta Haenisch; Andras Bilkei-Gorzo; Marc G Caron; Heinz Bönisch
Journal:  J Neurochem       Date:  2009-08-18       Impact factor: 5.372

9.  Paroxetine combined with a 5-HT(1A) receptor antagonist reversed reward deficits observed during amphetamine withdrawal in rats.

Authors:  Athina Markou; Amanda A Harrison; Jessica Chevrette; Daniel Hoyer
Journal:  Psychopharmacology (Berl)       Date:  2004-09-25       Impact factor: 4.530

10.  Differential autoreceptor control of extracellular 5-HT in guinea pig and rat: species and regional differences.

Authors:  Zoë A Hughes; Lee A Dawson
Journal:  Psychopharmacology (Berl)       Date:  2003-09-30       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.